SOUTH SAN FRANCISCO (dpa-AFX) - Omega Therapeutics, Inc. (OMGA) announced a clinical supply agreement with Roche to evaluate OTX-2002, the company's lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma, in combination with Roche's anti-PD-L1 therapy, atezolizumab, as part of Omega's Phase 1/2 MYCHELANGELO I clinical trial. Roche will supply atezolizumab. Omega will evaluate the combination as part of the overall conduct of the trial.
Mahesh Karande, CEO of Omega Therapeutics, said: 'Through the combination of two orthogonal treatments, OTX-2002 and atezolizumab, a leading anti-PD-L1 therapy, we aim to simultaneously disrupt multiple drivers of cancer progression with the goal of improving treatment outcomes.'
For More Such Health News, visit rttnews.com.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX